Role of insulin-like growth factor-i in diagnosis and management of acromegaly

Endocrine Practice

Volumn 10, Issue 4, 2004, Pages 362-371

  Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; BIOSYNTHESIS; BLOOD; HUMAN; PATHOPHYSIOLOGY; REVIEW;

ACROMEGALY; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 17144415263     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.10.4.362     Document Type: Review

References (63)

1. Melmed S. Acromegaly. N Engl J Med. 1990;322:966-977.
2. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med. 1993;86:293-299.
3. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am. 1992;21:669-692.
4. Melmed S. Tight control of growth hormone: an attainable outcome for acromegaly treatment. J Clin Endocrinol Metab. 1998;83:3409-3410.
5. Swearingen B, Barker FG II, Katznelson L, et al. Longterm mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998; 83:3419-3426.
6. al-Mefty O, Kersh JE, Routh A, Smith RR. The longterm side effects of radiation therapy of benign brain tumors in adults. J Neurosurg. 1990;73:502-512.
7. Van Cauter E, Kerkhofs M, Caufriez A, Van Onderbergen A, Thorner MO, Copinschi G. A quantitative estimation of GH secretion in normal man: reproducibility and relation to sleep and time of day. J Clin Endocrinol Metab. 1992;74:1441-1450.
8. Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218:585-587.
9. Tannenbaum GS, Epelbaum J, Bowers CY. Inter-relationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology. 2003; 144:967-974.
10. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157-198.
11. Hartman ML, Clayton PE, Johnson ML, et al. A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. J Clin Invest. 1993;91:2453-2462.
12. Veldhuis JD, Liem AY, South S, et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab. 1995;80:3209-3222.
13. Roberts CT Jr, Lasky SR, Lowe WL Jr, Seaman WT, LeRoith D. Molecular coding of rat insulin-like growth factor I complementary deoxyribonucleic acids: differential messenger ribonucleic acid processing of regulation by growth hormone in extrahepatic tissue. Mol Endocrinol. 1987;1:243-248.
14. Wang X, Darus CJ, Xu BC, Kopchick JJ. Identification of growth hormone receptor (GHR) tyrosine residues required for GHR phosphorylation and JAK2 and STAT5 activation. Mol Endocrinol. 1996;10:1249-1260.
15. Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989;10:68-91.
16. Mathews LS, Hammer RE, Behernger RR, et al. Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology. 1988;123: 2827-2833.
17. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-1) and type 1 IGF receptor (IGF1r). Cell. 1993;75:59-72.
18. Powell-Braxton L, Hollingshead P, Warburton C, et al. IGF-I is required for normal embryonic development in mice. Genes Dev. 1993;7:2609-2617.
19. Camacho-Hubner C, Woods KA, Miraki-Moud F, et al. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion. J Clin Endocrinol Metab. 1999;84:1611-1616.
20. Backeljauw PF, Underwood LE (GHIS Collaborative Group). Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - a clinical research center study. J Clin Endocrinol Metab. 1996;81:3312-3317.
21. Baumann G, Stolar MW, Buchanan TA. The metabolic clearance, distribution, and degradation of dimeric and monomeric growth hormone (GH): implications for the pattern of circulating GH forms. Endocrinology. 1986;119: 1497-1501.
22. Jones JI, Clemmons DR. Insulin-like growth factor and their binding proteins: biologic actions. Endocr Rev. 1995;16:3-34.
23. Underwood LE, Van Wyk JJ. Normal and aberrant growth. In: Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. 8th ed. Philadelphia, PA: WB Saunders, 1992: 1079-1138.
24. Monson JP, Cook DM, eds. Growth Hormone Deficiency in Adults: A Pocket Guide to Clinical Management. Yardley, PA; ApotheCom Associates LLC, 2003.
25. Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 1988;67:69-73.
26. Chernausek SD, Underwood LE, Utiger RD, Van Wyk JJ. Growth hormone secretion and plasma somatomedin-C in primary hypothyroidism. Clin Endocrinol (Oxf). 1983; 19:337-344.
27. Clemmons DR, Klibanski A, Underwood LE, et al. Reduction of plasma immunoreactive somatomedin-C during fasting in humans. J Clin Endocrinol Metab. 1981;53: 1247-1250.
28. Vaessen N, Heutink P, Janssen JA, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes. 2001;50:637-642.
29. Hall K, Hilding A, Thoren M. Determinants of circulating insulin-like growth factor-I. J Endocrinol Invest. 1999; 22(5 Suppl):48-57.
30. Clemmons DR. Insulin-like growth factor binding proteins. In: Kotyl JL, Goodman HM, eds. Handbook of Physiology: Hormonal Control of Growth. Vol 5. New York, NY: Oxford University Press, 1999: 513-631.
31. Grinspoon S, Clemmons D, Swearingen B, Klibanski A. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab. 1995;80:927-932.
32. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab. 2002;87:3537-3542.
33. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med. 1979;301:1138-1142.
34. Kim HJ, Kwon SH, Kim SW, et al. Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults. Horm Res. 2001;56:117-123.
35. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526-529.
36. Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab. 2002;87:3142-3147.
37. Rieu M, Girard F, Bricaire H, Binoux M. The importance of insulin-like growth factor I (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J Clin Endocrinol Metab. 1982;55:147-153.
38. Roelfsema F, Frolich M, Van Dulken H. Somatomedin-C levels in treated and untreated patients with acromegaly. Clin Endocrinol (Oxf). 1987;26:137-144.
39. Lindholm J, Giwercman B, Giwercman A, Astrup J, Bjerre P, Skakkebaek NE. Investigation of the criteria for assessing the outcome of treatment in acromegaly. Clin Endocrinol (Oxf). 1987;27:553-562.
40. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171-1177.
41. Wass JA, Clemmons DR, Underwood LE, Barrow I, Besser GM, Van Wyk JJ. Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Clin Endocrinol (Oxf). 1982;17:369-377.
42. Jasper H, Pennisi P, Vitale M, Mella A, Ropelato G, Chervin A. Evaluation of disease activity by IGF-I and IGF-binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score. J Endocrinol Invest. 1999;22:29-34.
43. Paramo C, Andrade MA, Fluiters E, Luna R, de la Fuente J, Garcia-Mayor RV. Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) level and IGF-I/IGFBP-3 ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly. Metabolism. 1997;46:494-498.
44. Arafah BM, Rosenweig JL, Fenstermaker R, Salazar R, McBride CE, Selman W. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly. J Lab Clin Med. 1987;109: 346-354.
45. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab. 1994;78:1312-1319.
46. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab. 1998;83:3808-3816.
47. Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab. 2001;86:259-266.
48. Oppizzi G, Petroncini MM, Dallabonzana D, et al. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation. J Clin Endocrinol Metab. 1986;63:1348-1353.
49. Peacey SR, Shalet SM. Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly. Ann Clin Biochem. 2001;38(Pt 4):297-303.
50. Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3. J Clin Endocrinol Metab. 2001;86:1091-1098.
51. Fukuda I, Hizuka N, Itoh E, et al. Acid-labile subunit in growth hormone excess and deficiency in adults: evaluation of its diagnostic value in comparison with insulin-like growth factor (IGF)-I and IGF-binding protein-3. Endocr J. 2002;49:379-386.
52. Marzullo P, Di Somma C, Pratt KL, et al. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab. 2001; 86:3001-3008.
53. Gama R, Labib M, Teale JD, Marks V. Acromegaly with a misleading normal plasma insulin-like growth factor 1. Ann Clin Biochem. 1989;26(Pt 1):102-103.
54. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab. 1998;83:2646-2652.
55. Acromegaly Therapy Consensus Development Panel. Consensus statement: benefits versus risks of medical therapy for acromegaly. Am J Med. 1994;97:468-473.
56. Melmed S, Casanueva FF, Cavagnini F, et al (Acromegaly Treatment Consensus Workshop Participants). Guidelines for acromegaly management. J Clin Endocrinol Metab. 2002;87:4054-4058.
57. Quarmby V, Quan C, Ling V, Compton P, Canova-Davis E. How much insulin-like growth factor I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy. J Clin Endocrinol Metab. 1998;83:1211-1216.
58. Clemmons DR. Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Horm Res. 2001;55(Suppl 2):73-79.
59. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279:563-566.
60. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351:1393-1396.
61. Orme SM, McNally RJ, Cartwright RA, Belchetz PE (United Kingdom Acromegaly Study Group). Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab. 1998;83:2730-2734.
62. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer. 2000;36:1224-1228.
63. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000;183:1-9.